{
  "id": 2297,
  "text": "\\mathrm { C x }$ functional assessment of cancer therapy-cervix FEM fixed-effects method <html><body><table><tr><td></td><td></td></tr><tr><td>FIGO fédération internationale de gynecologie et d'obstétrique</td><td>KCE centre fédéral d'expertise des soins de santé</td></tr><tr><td>FSFI female sexual functioning index</td><td>LACC locally advanced cervical cancer</td></tr><tr><td>FSS fertility sparing surgery</td><td>LARVH laparoscopic-assisted radical vaginal hysterectomy</td></tr><tr><td>FST fertility sparing treatment</td><td>LDR low-dose rate</td></tr><tr><td>GCC glassy cell carcinoma</td><td>LEEP loop electrosurgical excision procedure</td></tr><tr><td>GCIG gynecologic cancer intergroup</td><td>LH laparoscopic hysterectomy</td></tr><tr><td>GEC-ESTRO groupe européen de curiethérapie - european society for radiotherapy and oncology</td><td>LLETZ large loop excision of the transformation zone</td></tr><tr><td>GIN guidelines international network</td><td>LN lymph node</td></tr><tr><td>GTV-Tres residual gross tumor volume</td><td>LN+ positive lymph nodes</td></tr><tr><td>HAS haute autorité de santé</td><td>LND lymph node dissection</td></tr><tr><td>HDR high-dose rate</td><td>LVSI lymphovascular space involvement</td></tr><tr><td>H&E haematoxylin and eosin</td><td>M-H mantel- haenszel</td></tr><tr><td>HPV human papillomarivus</td><td>MD mean difference</td></tr><tr><td> HR hazard ratio</td><td> MRI magnetic resonance imaging</td></tr><tr><td>hsCRP high sensitivity C-reactive protein</td><td>MSAC medical services advisory committee</td></tr><tr><td> IAP immunosuppressive acidic protein</td><td> NA not available</td></tr><tr><td>ICG indocyanine green</td><td>NAB-paclitaxel nano-particule albumin bound paclitaxel</td></tr><tr><td>IES impact of events scale</td><td> NACT neoadjuvant chemotherapy</td></tr><tr><td>IGABT image guided adaptive brachytherapy</td><td>NCCN national comprehensive cancer network</td></tr><tr><td>IGRT image guided radiotherapy</td><td>NED no evidence of disease</td></tr><tr><td>IHC immunohistochemistry</td><td>NHMRC national health and medical research</td></tr><tr><td>IL-6 interleukin 6 IMRT intensity modulated radiotherapy</td><td>council</td></tr><tr><td>INAHTA international network of agencies for</td><td>NHS national health service NICE national institute for health and care</td></tr><tr><td>health technology assessment INCa institut national du cancer</td><td>excellence NICU neonatal intensive care unit</td></tr><tr><td>INESSS institut national d'excellence en sante et</td><td>nr not reported</td></tr><tr><td>en services sociaux IORT intraoperative radiation therapy</td><td>NSRS nerve-sparing radical surgery</td></tr><tr><td> IV inverse variance</td><td>NZGG new zealand guidelines group</td></tr></table></body></html> <html><body><table><tr><td>OH open hysterectomy</td><td>RR relative risk</td></tr><tr><td>OR odd ratio</td><td>RT radiation therapy</td></tr><tr><td>OS overall survival</td><td>SCC squamous cell carcinoma</td></tr><tr><td>OT ovarian transposition</td><td>SCC-Ag squamous cell carcinoma antigen</td></tr><tr><td>PALN para-aortic lymph node</td><td>SD stable disease</td></tr><tr><td>PALND para-aortic lymph node dissection</td><td>SDM standard differences in means</td></tr><tr><td>PDR pulsed-dose rate</td><td>SEER surveillance, epidemiology, and end results</td></tr><tr><td>PET positron emission tomography</td><td>SH simple hysterectomy</td></tr><tr><td>PET-CT positron emission tomography-</td><td> SIGN scottish intercollegiate guidelines network</td></tr><tr><td>computed tomography</td><td>SLN sentinel lymph node</td></tr><tr><td>PFS progression-free survival</td><td>SMC small cell carcinoma</td></tr><tr><td>PLN pelvic lymph node</td><td>SN sentinel node</td></tr><tr><td>PLND pelvic lymph node dissection</td><td> TATI tumour-associated trypsin inhibitor</td></tr><tr><td>pPROM preterm spontaneous rupture of membranes</td><td>TNF-α tumour necrosis factor alpha</td></tr><tr><td>PR partial response</td><td>TPA tissue polypeptide antigen</td></tr><tr><td>PROM premature rupture of membranes</td><td>US ultrasound</td></tr><tr><td>PTL preterm labour</td><td>VALRH vaginal-assisted laparoscopic radical</td></tr><tr><td>RCT randomized controlled trial</td><td>hysterectomy</td></tr><tr><td>REM random-effects method</td><td>VEGF vascular endothelial growth factor</td></tr><tr><td>RFS relapse-free survival</td><td>WG weeks gestation</td></tr><tr><td>RH radical hysterectomy</td><td>WMD weighted mean difference</td></tr></table></body></html> 18 References 1.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: \\mathrm { C x }$ functional assessment of cancer therapy-cervix FEM fixed-effects method <html><body><table><tr><td></td><td></td></tr><tr><td>FIGO fédération internationale de gynecologie et d'obstétrique</td><td>KCE centre fédéral d'expertise des soins de santé</td></tr><tr><td>FSFI female sexual functioning index</td><td>LACC locally advanced cervical cancer</td></tr><tr><td>FSS fertility spari\n\n<question>: ",
  "ChatGPT_response_0": "评估宫颈癌患者的功能状况可以通过多种方式进行。其中一种方法是使用包括 C x functional assessment of cancer therapy-cervix 和 FIGO 等评估工具。这些工具可以帮助医生评估患者的生活质量、身体功能、情绪状态以及性功能等方面的情况。同时，还可以考虑患者的症状、体重变化、疼痛程度和日常活动能力等因素来综合评估患者的功能状态。综合使用这些评估工具和指标可以更全面地了解患者的整体健康状况，有助于制定个性化的治疗方案和提供更有效的医疗护理。",
  "query": "您如何评估宫颈癌患者的功能状况？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 您如何评估宫颈癌患者的功能状况？\n\n<reference text>: \\mathrm { C x }$ functional assessment of cancer therapy-cervix FEM fixed-effects method <html><body><table><tr><td></td><td></td></tr><tr><td>FIGO fédération internationale de gynecologie et d'obstétrique</td><td>KCE centre fédéral d'expertise des soins de santé</td></tr><tr><td>FSFI female sexual functioning index</td><td>LACC locally advanced cervical cancer</td></tr><tr><td>FSS fertility sparing surgery</td><td>LARVH laparoscopic-assisted radical vaginal hysterectomy</td></tr><tr><td>FST fertility sparing treatment</td><td>LDR low-dose rate</td></tr><tr><td>GCC glassy cell carcinoma</td><t\n\n<reply>: ",
  "response": "评估宫颈癌患者的功能状况可以通过多种方式进行。其中一种方法是使用包括 C x functional assessment of cancer therapy-cervix 和 FIGO 等评估工具。这些工具可以帮助医生评估患者的生活质量、身体功能、情绪状态以及性功能等方面的情况。同时，还可以考虑患者的症状、体重变化、疼痛程度和日常活动能力等因素来综合评估患者的功能状态。综合使用这些评估工具和指标可以更全面地了解患者的整体健康状况，有助于制定个性化的治疗方案和提供更有效的医疗护理。"
}